(Credit: Karolina Grabowska from Pexels)
BOSTON — As healthcare costs continue to soar, a new study is offering a glimmer of hope for patients struggling with high prescription drug prices. The research, published in JAMA and conducted by a team of medical experts, reveals a set of innovative strategies that could help patients and their doctors navigate increasingly unaffordable medication costs.
The study’s most provocative takeaway? Nearly one in three adults in the United States struggles to afford their prescriptions. This startling statistic underscores the urgent need for solutions, especially for those with multiple chronic conditions, low socioeconomic status, or those who identify as Black or Latino.
So, why are prescription drugs so expensive in the U.S. compared to other high-income countries? The answer lies in a combination of factors, including patent-protected market exclusivity for brand-name drugs and complexities in how medications are reimbursed and distributed. Even patients with insurance can face high costs due to deductibles, co-payments, and coinsurance.
The researchers identified 7 key strategies to help patients afford their prescriptions:
- Co-payment cards
- Patient assistance programs
- Pharmacy coupons
- Direct-to-consumer pharmacies
- Public assistance programs
- International online pharmacies
- Real-time prescription benefit tools
Let’s dive into each of these strategies. Co-payment cards, offered by drug manufacturers, can lower out-of-pocket costs for privately insured patients taking brand-name drugs. For example, a co-payment card for a popular anticoagulant medication can reduce monthly costs to as little as $10, with a maximum annual benefit of $6,400.
For uninsured individuals or those with public insurance like Medicare Part D, patient assistance programs may be available if they meet financial eligibility criteria. These programs, offered by drug manufacturers or independent nonprofit organizations, can significantly reduce or even eliminate out-of-pocket costs for expensive medications.
Pharmacy coupons allow patients to purchase medications directly from pharmacies without using insurance. These coupons, available through smartphone apps or websites, can be particularly helpful for generic medications or drugs that are often subject to coverage restrictions.
The rise of direct-to-consumer pharmacies is changing the landscape. These new entrants in the U.S. prescription drug market offer a selection of drugs at transparent prices, sometimes lower than insurance-required out-of-pocket costs. Some big-box retailers and online pharmacies have embraced this model, with one company even offering unlimited access to several dozen commonly used generics for a $5-per-month subscription.
Public assistance programs, such as Medicaid and Medicare’s Extra Help program, provide crucial support for low-income individuals. These programs can significantly reduce out-of-pocket costs for eligible patients.
For those facing truly dire circumstances, the study suggests considering reputable international online pharmacies as a last resort. While this option comes with legal and safety considerations, it can provide significant savings for brand-name drugs that are 2 to 3 times more expensive in the U.S. than in other countries.
Lastly, real-time prescription benefit tools provide clinicians with information about coverage and out-of-pocket costs at the time of prescribing. These tools can help doctors and patients make more informed decisions about medication choices based on affordability.
While these strategies offer hope for many patients, the study’s authors emphasize that they are ultimately stopgap measures. The need for such a patchwork of solutions underscores the urgent need for systemic reforms in the U.S. healthcare system to address the root causes of high drug prices.
As patients and doctors navigate this complex landscape, the study provides a valuable roadmap for finding affordable medication options. By understanding and utilizing these strategies, more Americans may be able to access the treatments they need without breaking the bank.
Paper Summary
Methodology
The researchers conducted a comprehensive review of existing literature and data on prescription drug costs and affordability strategies in the United States. They analyzed the benefits and limitations of seven different approaches to helping patients afford their medications, including co-payment cards, patient assistance programs, pharmacy coupons, direct-to-consumer pharmacies, public assistance programs, international online pharmacies, and real-time prescription benefit tools. The team then developed an algorithm to help clinicians identify appropriate strategies based on a patient’s health insurance status and the type of drug prescribed (brand-name vs. generic).
Key Results
The study found that each of the seven strategies had potential benefits for certain patient populations but also came with limitations. Co-payment cards were found to be effective for privately insured patients taking brand-name drugs, while patient assistance programs could help uninsured or underinsured individuals who meet specific financial criteria. Pharmacy coupons and direct-to-consumer pharmacies were identified as potentially useful for patients purchasing generic medications without insurance.
The researchers also noted the potential savings from international online pharmacies for brand-name drugs, despite legal and safety concerns. Real-time prescription benefit tools showed promise in helping clinicians make more informed prescribing decisions based on patient out-of-pocket costs.
Study Limitations
The study acknowledges several limitations to the strategies presented. Many of the approaches, such as co-payment cards and patient assistance programs, are not available to all patients and may have specific eligibility requirements. The use of international online pharmacies comes with legal and safety risks.
Additionally, while these strategies can help individual patients afford their medications, they do not address the underlying systemic issues causing high drug prices in the United States.
Discussion & Takeaways
The researchers emphasize that while these strategies can provide tangible solutions for patients struggling with high drug costs, they ultimately highlight the need for broader policy reforms in the U.S. prescription drug market. The study suggests that expanding Medicare price negotiation and out-of-pocket limits to all patients in the U.S. could be a step toward more comprehensive reform. In the meantime, the authors stress the importance of clinicians understanding and utilizing these strategies to help patients navigate the complex landscape of prescription drug affordability.
Funding & Disclosures
The study was funded by a grant from Arnold Ventures, with additional support from the Commonwealth Fund, the Elevance Health Public Policy Institute, the Greenwall Foundation, and the National Academy for State Health Policy. One of the authors reported receiving personal payments from Alosa Health and serving as an expert witness in cases related to generic drug pricing and pharmaceutical mergers.
